首页 News 正文

On December 21st local time, AstraZeneca announced that its and Ionis company's eplontersen have been approved in the United States. Eplontersen is an antisense oligonucleotide (ASO) therapy for the treatment of hereditary thyroxine protein (TTR) mediated amyloidosis multiple neuropathy (ATTRv PN).
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

因醉鞭名马幌 注册会员
  • 粉丝

    0

  • 关注

    0

  • 主题

    43